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CD4R cell count recovery following initiation
of HIV antiretroviral therapy in older
childhood and adolescence
Victoria Simmsa, Sarah Rylanceb, Tsitsi Bandasonc, Ethel Dauyac,
Grace McHughc, Shungu Munyatic, Hilda Mujurud,
Sarah L. Rowland-Jonese, Helen A. Weissa and Rashida A. Ferrandc,f
Objective: To investigate CD4þ cell count recovery following ART initiation in
perinatally HIV-infected children diagnosed in later childhood.
Design: Observational prospective cohort study of newly diagnosed children aged
6–15 in Harare, Zimbabwe.
Methods: Participants were enrolled into a cohort at seven primary healthcare clinics
between January 2013 and January 2015. ART was initiated according to national
guidelines and CD4þ cell counts were performed 6-monthly over 18 months. The
relationship between CD4þ cell count and time on ART was investigated using
regression analysis with fixed (population) and random (individual) effects, and age
at ART initiation as a covariate.
Results: Of the 307 participants who initiated ART, the median age at initiation was
11.7 years (interquartile range 9.6–13.8). The addition of an individual intercept and
slope as random effects significantly improved the model fit compared with a fixed
effects-only model. CD4þ response (using a square-root transformation) was best
modelled using a two-knot linear spline, with significant effects of time on ART and
age at ART initiation. Younger children had a higher CD4þ cell count at ART initiation
(17.9 cells/ml per year of age), an accelerated increase during the first 3 months on
ART (38.9 cells/ml per year of age at day 84), and a sustained higher CD4þ cell count.
Conclusion: Earlier ART initiation in older children is associated with accelerated CD4þ
cell count recovery and lasting immune reconstitution. Our findings support WHO
guidance recommending ART initiation in all children, irrespective of disease stage
and CD4þ cell count. Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc.
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Keywords: adolescent, CD4þ cell count, HIV, immune reconstitution
Introduction
Most children living with HIV acquired the infection
perinatally. In the pre-ART era, HIV-positive infants in
sub-Saharan Africa had a 50% risk of mortality before age
2 years [1]. However, as HIVepidemics matured, survival
estimates were successively revised upwards, and it is
estimated that about one-third of perinatally infected
infants have ‘slow progressing’ HIV disease, with a
median survival of at least 16 years without treatment [2].
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Large numbers of children now present with undiagnosed
perinatally acquired HIV in older childhood and
adolescence in sub-Saharan Africa [3], where over 80%
of the world’s HIV-infected children live [4].
For infants, ART initiation regardless of CD4þ cell count
or disease stage substantially reduces mortality [5] and has
been recommended since 2010 [6]. In older children and
adolescents, the evidence for reduced mortality is less
clear. A systematic review of antiretroviral therapy (ART)
for children aged under 3 years found few studies [7], and
the only trial in older children was underpowered and
showed no mortality benefit of early initiation [8]. In the
absence of clear evidence, and to simplify HIV treatment
programmes, guidance for children aged at least 5 years
followed that for adults, with ART initiation recom-
mended for those with clinical WHO stage 3 or 4 disease,
or low CD4þ cell count (below 350 cells/ml in 2010 [6],
with the threshold raised to 500 cells/ml in 2013 [9]).
More recently, the TEMPRANO and START trials
showed that ART initiation before CD4þ cell count
dropped below 500 cells/ml reduced morbidity [10,11]
and the HPTN 052 trial showed that it also reduced
sexual transmission [12]. As a result, the most recent
WHO guidance (from 2016) recommends immediate
ART initiation for all individuals living with HIV,
irrespective of CD4þ cell count and disease stage [13].
Again, the guidance has also been applied to children even
though based on evidence from trials conducted in adults.
There are concerns related to long-term toxicity and
development of resistance because of poor adherence to
ART, particularly for children who will be on ART a
decade or more longer than adults initiating ART.
Conversely, there are likely benefits of earlier ART
initiation. The aim of this study is to estimate change in
CD4þ cell count over time in a cohort of children
diagnosed with HIV in older childhood, and to assess
whether age affected CD4þ cell count recovery.
Methods
Participants aged 6–15 years were recruited from seven
public sector primary healthcare clinics in Harare,
Zimbabwe between January 2013 and January 2015,
following provider-initiated HIV testing and counselling.
Those who tested HIV-positive were offered enrolment
into a prospective cohort study. Exclusion criteria
included living outside Harare or choosing not to seek
HIV care at one of the study clinics. Participants were
invited for follow-up visits at 3-monthly intervals for
assessment of clinical status, up until 18 months
postenrolment. Within the cohort, participants who
consented to home visits were enrolled into the ZENITH
randomized controlled trial, reported elsewhere [14].
The guideline in use in January 2013 stated that children
should be initiated on ART at a CD4þ cell count below
350 cells/ml or if they had WHO stage 3 or 4 HIV disease
[6]. In March 2014, Zimbabwe adopted the new WHO
guidelines [9], with a revised threshold for ART initiation
of 500 CD4þcells/ml.
CD4þ cell count was measured at 3 and 6 months
postinitiation, and otherwise 6-monthly, with an Alere
PIMA CD4 (Waltham, Massachusetts, USA) machine.
Participant data were recorded by a study nurse on paper
clinical report forms and entered into an MS Access
database using Cardiff TELEFORM Intelligent Charac-
ter Optical Mark Recognition Software (Version 10.9).
Statistical analyses were performed using R v3.4.1 and
Stata v14.0 (StataCorp, College Station, Texas, USA).
To explore the relationship between the CD4þ cell count
and the explanatory variables, time on ART and age at
ART initiation, we performed linear mixed-effects
regression modelling of longitudinal data. Time was
modelled using a linear spline. Splines provide a flexible
way of modelling response curves over time using
standard linear mixed modelling software. We used the
simplest family of splines, in which the response curve is a
continuous, piece-wise linear function. Comparison of
nested models was made using the likelihood ratio test. A
linear spline model was explored incorporating zero, one
or two knots to determine which best fitted the data. The
first knot was a priori positioned at time 0, because of the
biological plausibility of a change in CD4þ response at
ART initiation. The optimal position for the second knot
was ascertained by calculating the log-likelihood value for
a knot on each day.
To build the model, we first used ordinary least squares
regression, then added a random intercept and then a
random slope. Next we added the spline terms one by
one, then age at ART initiation, and finally an interaction
between age and time. At each stage, we used a likelihood
ratio test to determine whether the increased complexity
was justified.
The residuals were plotted against the fitted values for the
CD4þ response model to verify the assumptions of
homogenous variance and normally distributed errors. As
a sensitivity analysis, we fitted the same linear spline model to
a censoreddataset, which consistedonlyof data between 100
days preinitiation and 600 days postinitiation of ART. This
was to ensure that the model was not unduly influenced by
sparse data at the extreme ends of the follow-up period.
Ethical approval for the study was obtained from the
Medical Research Council of Zimbabwe (MRCZ/A/
1676) and the Ethics Committees of Harare City Health
Services, the Biomedical Research and Training Institute
(AP 108/2012) and the London School of Hygiene and
Tropical Medicine (6305).
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Results
Between 23 January 2013 and 23 January 2015, 385
children and adolescents were enrolled into the cohort, of
whom 307 (79.7%) initiated ART during follow-up.
Reasons for noninitiation were: no CD4þ cell count
below the threshold for ART initiation (350 cells/ml prior
to March 2014, 500 cells/ml thereafter; n¼ 78); less than a
month of follow-up before transferring out (n¼ 5) or
being lost to follow-up (n¼ 1); only became eligible for
ART at the last follow-up visit (n¼ 4).
Participants were aged 6–15 years at enrolment and 6–17
years at ART initiation (Table 1). Of the 307 participants
who initiated ART, about half were female patients
(52.1%) and almost all (96.7%) acquired HIV perinatally,
defined as a history of maternal or natural sibling HIV
or death, and self-report of no sexual debut, blood
transfusion or surgery [15]. There were a total of 1155
CD4þ cell count test results, collected between 898 days
prior to ART initiation and 1099 days postinitiation
(median 149 days postinitiation, IQR 9 to 343), with a
median follow-up per person of 516 days. Most
participants (n¼ 206; 67.1%) initiated ART within the
first 4 weeks of enrolment. Following Zimbabwean
national guidelines, all children aged less than 10 years or
weighing less than 25 kg were initiated on zidovudine, all
those weighing more than 35 kg were initiated on
tenofovir, and those in the middle range were initiated on
either (including 10 on d4T).
The square root transformation of CD4þ cell count
resulted in a more symmetrical data distribution than
either the raw values or a log transformation (Fig. 1), and
was the selected outcome measure. A random intercept
model was a much better fit than a fixed-effects model,
with a likelihood ratio test result of 660.1 (P< 0.001) A
model with a random intercept and slope was slightly
better than a random intercept alone (likelihood ratio
test¼ 28.8, P< 0.001). The best-fitting linear spline
model of CD4þ cell count results incorporated two
knots, the first fixed a priori at 0 days after ART initiation
and the second, established using log-likelihood values, at
84 days postinitiation (Supplementary Figure 1, http://
links.lww.com/QAD/B311). Compared to a one-knot
model the likelihood ratio chi-square value was 198.4
(P< 0.001). Age at ART initiation improved the fit both
as a main effect (likely-hood ratio test¼ 24.8, P< 0.001)
and again as an interaction effect of age at ART initiation
with time (likely-hood ratio test¼ 13.5, P¼ 0.004).
The final model showed that CD4þ cell count decreased
over time until ART initiation, then increased until the
second knot at day 84, and then remained steady
(Table 2). CD4þ cell count was significantly associated
with age as a fixed effect. On the day of initiation, one
additional year of age at ART initiation was associated
with a 17.9-point decrease in CD4þ cell count. Over
time the effect of age on CD4þ cell count increased. For
example, after 84 days on ART, each one-year increase in
age was associated with a decrease in CD4þ cell count of
38.9 cells/ml. On day 84 postinitiation, the estimated
average CD4þ cell count was 696 cells/ml for a child who
started ART aged 6 years; 518 cells/ml for a child who
started ART aged 10 years; and 332 cells/ml for age at
ART initiation of 15 years (Fig. 2).
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Table 1. Characteristics of study participants (NU307).
Variable Categories N (%)
N 307 (100)
Sex Male 147 (47.9)
Female 160 (52.1)
Age at ART initiation (years) 6–9 98 (31.9)
10–13 146 (47.6)
14–17 63 (20.5)
CD4þ cell count at enrolment
(cells/ml)
0–99 49 (16.0)
100–199 37 (12.1)
200–349 89 (29.0)
350–499 66 (21.5)
500þ 66 (21.5)
Time from enrolment
to ART initiation
Up to 4 weeks 206 (67.1)
>4 weeks to 1 year 80 (26.1)
>1 year 21 (6.8)
ART regimen at initiation TDF/3TC/EFV 66 (25.3)
TDF/3TC/NVP 62 (23.8)
TDF/3TC/ATV 1 (0.4)
ZDV/3TC/EFV 32 (12.3)
ZDV/3TC/NVP 90 (34.5)
d4T/3TC/EFV 3 (1.2)
d4T/3TC/NVP 7 (2.7)
Unknown 46
Number of CD4þ cell
count test results
1 35 (11.4)
2 30 (9.8)
3 50 (16.3)
4 66 (21.5)
5 111 (36.2)
6–7 15 (4.9)
ART, antiretroviral therapy.
Fig. 1. Square root of CD4R cell count over time since
antiretroviral therapy initiation with locally weighted scat-
terplot smoothing (LOWESS) (NU1155 observations).
Before ART initiation, the interaction effect of age at
initiation was statistically significant but negligible in its
effect. Once participants were on ART the trajectories
diverged, with younger children gaining a greater rise in
CD4þ cell count (a difference in square root of CD4þ of
0.005, P¼ 0.01).
For the sensitivity analysis, 120 outlier observations at the
extreme ends of the observation period were dropped,
and the models were refitted (Supplementary Table 1,
http://links.lww.com/QAD/B311). Results were similar
(Supplementary Figure 2, http://links.lww.com/QAD/
B311). Residuals of both models were unbiased and
homoscedastic.
Discussion
Among children and adolescents living with HIV in
Zimbabwe, CD4þ cell count increased in the first 3
months following ART initiation, and then stabilized.
The first 3 months of ARTappear to be a key window for
immune reconstitution in children. Immune reconstitu-
tion in children is qualitatively and mechanistically
different from adults, probably because of greater
involvement of the naı¨ve T-cell pool and a more active
thymus gland [16]. T cells are formed in bone marrow and
migrate to the thymus where they mature. From
childhood, the thymus begins to atrophy, although it
still produces some new T cells throughout life. Adults
have a biphasic response to ART, with a rapid increase in
memory CD4þ cells followed by a slower, smaller
increase in naı¨ve CD4þ cells [17]. In contrast, children
demonstrate peripheral CD4þ repopulation through
increased thymic naı¨ve T-cell output, with only a small
increase in memory CD4þ cells [17,18]. For this reason,
the reference curves for CD4þ cell count response in the
first 9 months of ART, based on data from Europe [18],
cannot be applied to children.
Children who initiated ART at a younger age showed a
greater immediate benefit, which was sustained over
time. Among adults, older age has also been associated
with poorer CD4þ response to ART [18], but not to the
extent observed among children in this study. In our
study, older participants had lower CD4þ cell counts at
ART initiation, and poorer immunological recovery in
the critical 3-month period after initiation. As a result,
the difference in CD4þ cell count between age groups
was greater in participants who were stable on ART than
among those not yet initiated on ART. The missed
opportunity for recovery in older children and adoles-
cents had long-lasting consequences, as they remained at a
lower average CD4þ cell count to the end of follow-up.
For this cohort, low CD4þ cell count at baseline was a
risk factor for other adverse outcomes, including
increased risk of hospital admission and mortality, as
shown previously [19]. Of 13 children who died during
follow-up, 11 had a CD4þ cell count below 350 cells/ml
at enrolment [20]. There are two possible causes of the
lower CD4þ cell count at baseline and poorer immune
recovery of adolescents compared with younger children.
Firstly, among perinatally infected children, older age
corresponds to later diagnosis. Children who were older
at ART initiation had, therefore, been immunosup-
pressed for a longer period. Secondly, adolescents may
have limited capacity for rapid immunological recovery,
as thymic involution has already advanced but a memory
T-cell reserve is not yet established. HIV-infected children
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Table 2. Results of linear spline model of square root of CD4R cell count over time around antiretroviral therapy initiation (NU1155
observations).
Parameter Value (95% CI) SE P value
Days pre-ART 0.02 (0.04 to 0.00) 0.01 0.08
0–84 days post-ART 0.13 (0.09–0.17) 0.02 <0.01
>84 days post-ART 0.11 (0.15 to 0.08) 0.02 <0.1
Age at ART initiation (years) 0.54 (0.84 to 0.25) 0.15 <0.01
Interaction of days pre-ART with age at ART initiation 0.00 (0.00 to 0.00) 0.00 0.74
Interaction of 0–84 days post-ART with age at ART initiation 0.01 (0.01 to 0.00) 0.00 0.01
Interaction of >84 days post-ART with age at ART initiation 0.00 (0.00–0.01) 0.00 0.01
Intercept 22.38 (18.97–25.79) 1.74 <0.01
ART, antiretroviral therapy; CI, confidence interval.
Fig. 2. Fitted CD4R cell count over time since antiretroviral
therapy initiation, by age at antiretroviral therapy initiation
(NU1155 observations).
have a smaller thymus than HIV-exposed but uninfected
children at age 3 months [21], and early thymic involution
is associated with rapid disease progression [22]. Delayed
ART initiation in children may thus have a dual effect. As
well as prolonging the duration of untreated infection, it
also raises the age of ART initiation, and so limits the
child’s capacity for immunological recovery. This would
explain why a year’s delay in a child has more effect on
CD4þ cell count than a year’s delay for an adult.
Our results are comparable with other studies exploring
CD4þ cell count reconstitution following ART initiation
in children. Recent studies of HIV-infected children
starting ART in Uganda, Zimbabwe [23], and Europe
[24] have described a nonlinear model for CD4þ
reconstitution, with a rapid rise in CD4þ cell count
reaching a plateau, which varied by age. However, a
quarter of children did not demonstrate this asymptotic
immune reconstitution. In these studies, the investigators
fitted a nonlinear mixed-effects model, which predicted
higher long-term CD4þ cell counts for children starting
ART at a younger age and with a higher initial count
[23,24], and the trajectory of increase was steeper in
younger children. This is consistent with our finding that
age at ART initiation was associated with both the level of
CD4þ cell count at ART initiation and the rate of change
in CD4þ cell count after ART initiation. The cohort
from Uganda and Zimbabwe, part of the ARROW trial,
benefited from a longer follow-up (median 4 years) with
CD4þ cell count measured every 12 weeks [23].
Strengths of this study include the prospective cohort
design, and the fact that participants received care in the
public sector, making the findings more generalizable.
The use of splines revealed that CD4þ recovery is
concentrated within a short 3-month period, and the use
of interaction and random slopes allowed for the effect of
age on CD4þ cell count to change over time. Longer
term follow-up of cohorts are needed to measure the
effects of ART toxicity or resistance development, and to
understand the long-term CD4þ response as children
grow up. Failure to achieve long-term CD4þ cell count
reconstitution is associated with poor clinical outcomes.
Perinatally infected cohorts in the USA had a higher
rate of advanced disease-defining events and mortality
at lower CD4þ cell counts, up to age 30 [25]. Even
small CD4þ cell count deficits are associated with
increased risk of cardiovascular disease, stroke, and
cancer in adult HIV patients [26,27]. Additionally, CD4þ
cell count is only one element of immunological
health. A study of children and adolescents in Kenya
found that after ART initiation, CD4þ cell count quickly
recovered to levels normal for the HIV-negative
population, but CD4þ:CD8þ ratio and plasma-soluble
CD14þ did not [28].
A recent review of the benefits and risks of universal ART
for children concluded that there is evidence of reduced
morbidity, improvement of growth, and better immune
recovery [29]. However, risks remain in terms of drug
toxicity, development of resistance because of poor
adherence, and the challenges of implementation,
especially in resource-limited settings. This study adds
to the evidence on immunological decline and reconsti-
tution in children, and provides clinical evidence to
support the policy of universal ART in older children
and adolescents to maximise the potential gains from
treatment.
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